Advertisement

Risk Factors for Hepatocellular Carcinoma Among Chronic Hepatitis C Patients Treated with Interferon

  • Akinori Kasahara
  • Norio Hayashi
  • Shinichi Kakumu
  • Kendo Kiyosawa
  • Kiwamu Okita
  • The Osaka Liver Disease Study Group
Conference paper

Abstract

In Japan, the incidence of hepatocellular carcinoma (HCC) has been increasing over the last 30 years, and epidemiological surveys have shown that as a causative agent, hepatitis C virus (HCV) is more common than hepatitis B virus (HBV). Chronic hepatitis C has been demonstrated to evolve to cirrhosis and HCC [1–3]. The HCC occurrence rate in cirrhotic patients with anti-HCV has been reported to increase steadily with a yearly incidence of 1.4%–7% [4–6]. Thus, a majority of cases with chronic HCV infection progress slowly to liver cirrhosis and HCC.

Keywords

Chronic Hepatitis Liver Cirrhosis Interferon Therapy Interferon Treatment Million Unit 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    DiBisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ (1991) Long-term clinical and histological follow-up of chronic posttransfusion hepatitis. Hepatology 14:969–974CrossRefGoogle Scholar
  2. 2.
    Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nagano Y, Furuta S, et al (1990) Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma. Analysis by detection of antibody to hepatitis C virus. Hepatology 12:671–675Google Scholar
  3. 3.
    Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M (1995) Incidence of hepatocellular carcinoma in chronic hepatitis B and C. A prospective study of 251 patients. Hepatology 21:650–655Google Scholar
  4. 4.
    Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, Kumada H, et al (1993) A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 18:47–53PubMedCrossRefGoogle Scholar
  5. 5.
    Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, et al (1997) Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112:463–472PubMedCrossRefGoogle Scholar
  6. 6.
    Oka H, Kurioka N, Kim K, Kanno T, Kuroki T, Mizoguchi Y, Kobayashi K (1990) Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 12:680–687PubMedCrossRefGoogle Scholar
  7. 7.
    Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Rerrilo RP, Carey W, et al (1989) Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized controlled trial. N Engl J Med 321:1501–1506Google Scholar
  8. 8.
    Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, et al (1989) Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double blind placebo-controlled trial. N Engl J Med 321:1506–1510Google Scholar
  9. 9.
    Hagiwara H, Hayashi N, Mita E, Ueda K, Takehara T, Kasahara A, Fusamoto H, et al (1992) Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-a. Hepatology 15:37–41PubMedCrossRefGoogle Scholar
  10. 10.
    Hagiwara H, Hayashi N, Mita E, Takehara T, Kasahara A, Fusamoto H, Kamada T (1993) Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 104:877–883PubMedGoogle Scholar
  11. 11.
    Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, Kato M, et al (1995) Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology 21:291–297PubMedCrossRefGoogle Scholar
  12. 12.
    Hiramatsu N, Hayashi N, Kasahara A, Hagiwara H, Takehara T, Haruna Y, Naito M, et al (1995) Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha. J Hepatol 22:135–142PubMedCrossRefGoogle Scholar
  13. 13.
    Hagiwara H, Hayashi N, Kasahara A, Oshita M, Katayama K, Kato M, Masuzawa M, et al (1996) Treatment with recombinant interferon-α 2a for patients with chronic hepatitis C: predictive factors for biochemical and virologic response. Scand J Gastroenterol 31:1021–1026PubMedCrossRefGoogle Scholar
  14. 14.
    Kuzushita N, Hayashi N, Katayama K, Kanto T, Oshita M, Hagiwara H, Kasahara A, et al (1997) High levels of serum interleukin-10 are associated with a poor response to interferon treatment in patients with chronic hepatitis C. Scand J Gastroenterol 32:169–174PubMedCrossRefGoogle Scholar
  15. 15.
    Kasahara A, Hayashi N, Mochizuki K, Oshita M, Katayama K, Kato M, Masuzawa M, et al (1997) Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response. J Hepatol 26:574–583Google Scholar
  16. 16.
    Yuki N, Hayashi N, Kasahara A, Hagiwara H, Takehara T, Oshita M, Katayama K, et al (1995) Pretreatment viral load and response to prolonged interferon-α course for chronic hepatitis C. J Hepatol 22:457–463PubMedCrossRefGoogle Scholar
  17. 17.
    Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, Tanaka T, et al (1992) Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 73:673–679PubMedCrossRefGoogle Scholar
  18. 18.
    Tanaka T, Tsukiyama-Kohara K, Yamaguchi K, Yagi S, Tanaka S, Hasegawa A, Ohta N, et al (1994) Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology 19:1347–1353PubMedCrossRefGoogle Scholar
  19. 19.
    Lau YN, Davis G, Kniffen J, Qian K-P, Urdea MS, Chan CS, Mizokami M, et al (1993) Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 341:1501–1504PubMedCrossRefGoogle Scholar
  20. 20.
    Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N, Nakamura A, et al (1997) Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Gastroenterology 113:558–566PubMedCrossRefGoogle Scholar
  21. 21.
    Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, et al (1981) Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431–435PubMedCrossRefGoogle Scholar
  22. 22.
    Kasahara A, Hayashi N, Mochizuki K, et al. (1998) Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic Hepatitis C. Hepatology 27:1394–1402PubMedCrossRefGoogle Scholar
  23. 23.
    Hagiwara H, Hayashi N, Mita E, Naito M, Kasahara A, Fusamoto H, Kamada T (1993) Quantitation of hepatitis C virus RNA in serum of asymptomatic blood donors and patients with type C chronic liver disease. Hepatology 17:545–550PubMedCrossRefGoogle Scholar
  24. 24.
    Jouet P, Roudot-Thoraval F, Dhumeaux D, Metreau JM (1994) Comparative efficacy of interferon alpha in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology 106:686–690PubMedGoogle Scholar
  25. 25.
    Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, et al (1995) Randomized trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346:1051–1055PubMedCrossRefGoogle Scholar
  26. 26.
    Mazzelia G, Accogli E, Sottili S, Festi G, Orsini M, Salzetta A, Novelli V, et al (1996) Alpha-interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 24:141–147CrossRefGoogle Scholar
  27. 27.
    Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, et al (1993) Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328:1797–1801PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 1999

Authors and Affiliations

  • Akinori Kasahara
    • 1
    • 2
  • Norio Hayashi
    • 2
  • Shinichi Kakumu
    • 3
  • Kendo Kiyosawa
    • 4
  • Kiwamu Okita
    • 5
  • The Osaka Liver Disease Study Group
  1. 1.Department of General MedicineOsaka University HospitalSuita, OsakaJapan
  2. 2.First-Department of MedicineOsaka University School of MedicineSuita, OsakaJapan
  3. 3.First-Department of MedicineAichi Medical SchoolNagakute-cho, AichiJapan
  4. 4.Second-Department of MedicineShinshu University School of MedicineMatsumoto, NaganoJapan
  5. 5.First-Department of MedicineYamaguchi University School of MedicineOoaza, Ube, YamaguchiJapan

Personalised recommendations